We can’t show the full text here under this license. Use the link below to read it at the source.
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
Effects of survodutide on people with BMI over 27, analyzed by sex and starting BMI
AI simplified
Abstract
After 46 weeks, females experienced greater reductions in bodyweight and waist circumference than males following treatment with survodutide.
- Participants with a lower baseline body mass index (BMI) exhibited greater proportional reductions in bodyweight compared to those with a higher baseline BMI.
- Conversely, reductions in waist circumference were greater in participants with a higher baseline BMI.
- Rates of adverse events were similar across different subgroups categorized by sex and baseline BMI.
- Nausea was the most commonly reported gastrointestinal adverse event in all subgroups.
- Survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference compared to placebo.
AI simplified